About OxThera
OxThera is a company based in Stockholm (Sweden) founded in 2005. OxThera has raised $93.1 million across 6 funding rounds from investors including HHS, Idinvest Partners and Kurma Partners. OxThera offers products and services including Oxabact. OxThera operates in a competitive market with competitors including Evelo Biosciences, Calliditas Therapeutics, DermBiont, Vedanta Biosciences and Unicycive, among others.
- Headquarter Stockholm, Sweden
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Oxthera Ab
-
Annual Revenue
$252.23 K (USD)48as on Dec 31, 2019
-
Net Profit
-$19.97 M (USD)-38as on Dec 31, 2019
-
EBITDA
Not available
-
Total Equity Funding
$93.1 M (USD)
in 6 rounds
-
Latest Funding Round
$222.83 K (USD), Grant
Sep 01, 2019
-
Investors
HHS
& 11 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of OxThera
OxThera offers a comprehensive portfolio of products and services, including Oxabact.
Orally administered treatment to reduce oxalate in Primary Hyperoxaluria patients.
People of OxThera
Unlock access to complete
Unlock access to complete
Funding Insights of OxThera
OxThera has successfully raised a total of $93.1M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $222.83 thousand completed in September 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in OxThera
OxThera has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Idinvest Partners and Kurma Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments in life sciences businesses are managed.
|
Locked | Locked | Locked | |
|
Ysios Capital is recognized as a leading life sciences investor.
|
Locked | Locked | Locked | |
|
Investments are made by Sunstone in early-stage European companies.
|
Locked | Locked | Locked |
Investor details for OxThera
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OxThera
Investment portfolio details for OxThera
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - OxThera
Detailed financials for OxThera
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Oxthera Comparisons
Peer comparison for OxThera
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OxThera
OxThera operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Evelo Biosciences, Calliditas Therapeutics, DermBiont, Vedanta Biosciences and Unicycive, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for inflammatory diseases, COVID-19, and cancer are developed.
|
|
| Locked | Locked | Locked |
Provider of small molecule based drug for inflammatory kidney disease
|
|
| Locked | Locked | Locked |
Microbial therapeutics for skin diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for infectious and autoimmune diseases are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapies for kidney diseases are developed.
|
|
| Locked | Locked | Locked |
Provider of DNA-based pathogen testing kits
|
Detailed competitors of OxThera
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oxthera
Complete news archive for OxThera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OxThera
OxThera was founded in 2005.
OxThera is headquartered in Stockholm, Sweden.
OxThera is a funded company, having raised a total of $93.1M across 6 funding rounds to date.
Annual revenue of OxThera is $252.23K as on Dec 31, 2019.
Provider of microbial-based drug products to treat hyperoxaluria. They develop products, based on cell and enzyme-based proprietary technologies, for metabolic disorders based on excess oxalate from endogenous and exogenous sources. Oxabact delivers an orally delivered composition of live bacteria, Oxalobacter Formigenes, and is primarily targeting the orphan disease Primary Hyperoxaluria. The other product Oxazyme is a non-systemic orally delivered drug composed of recombinant oxalate decarboxylase for treatment of Hyperoxaluria and to prevent the formation of calcium-oxalate kidney stones, and in phase 3 of the clinical trial.
OxThera's top competitors include PathogenDX, Calliditas Therapeutics and Manus Bio.
OxThera offers Oxabact.
OxThera has 12 investors. Key investors include HHS, Idinvest Partners, Kurma Partners, Life Sciences Partners, and Q-Med.